As reported earlier, Oppenheimer analyst Esther Rajavelu initiated coverage of Arrowhead with a Perform rating, saying she values the shares in a range of $60-$67. Rajavelu said that she believes the company is in the beginning phases of leveraging its platform to diversifty its pipeline and engage in commercial value creation over time. The analyst added that she likes its validated RNAi technology with potential applicability in multiple tissue types, its clinical stage pipeline with optionality to pursue large or orphan indications, and its recently funded balance sheet.